DRW Securities’s Pacific Biosciences PACB Stock Holding History

DRW Securities’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,565	Closed	-$46.9K	–	1349
2026 Q1	$46.9K	Buy	+35,565	New	+$63.6K	﹤0.01%	1208

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

DRW Securities's PACB Position: Q2 2026 in Review

DRW Securities sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 35,565 shares — an estimated $46.9K sold.

DRW Securities first reported a position in PACB in Q1 2026 and held it in 1 quarter. The position peaked at $46.9K in Q1 2026. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

DRW Securities reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 35,565 Pacific Biosciences shares in Q2 2026, an estimated $46.9K.
DRW Securities first reported a position in Pacific Biosciences in Q1 2026 and held it in 1 quarter.
DRW Securities's Pacific Biosciences position peaked at $46.9K in Q1 2026.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.